Abstract
Primary hepatocellular carcinoma (HCC) is a significant human cancer globally, with poor prognosis. New and efficacious therapy strategies are needed as well as new biomarkers for early detection of at-risk patients. In this review, we discuss select microarray studies of human HCCs, and propose a gene signature that has promise for clinical/translational application. This gene signature combines the proliferation cluster of genes and the hepatic cancer initiating/stem cell gene cluster for identification of HCCs with poor prognosis. Evidence from cell-based assays identifies the existence of a mechanistic link between these two gene clusters, involving the proliferation cluster gene polo-like kinase 1 (PLK1). We propose that PLK1 is a promising therapy target for HCC.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antigens, Neoplasm / genetics
-
Antigens, Neoplasm / metabolism
-
Carcinoma, Hepatocellular / genetics*
-
Cell Adhesion Molecules / genetics
-
Cell Adhesion Molecules / metabolism
-
Cell Cycle Proteins / genetics
-
Cell Cycle Proteins / metabolism
-
Epithelial Cell Adhesion Molecule
-
Gene Expression Profiling
-
Gene Expression Regulation, Neoplastic / genetics
-
Humans
-
Liver Neoplasms / genetics*
-
Multigene Family
-
Neoplastic Stem Cells / metabolism
-
Polo-Like Kinase 1
-
Polycomb-Group Proteins
-
Protein Serine-Threonine Kinases / genetics
-
Protein Serine-Threonine Kinases / metabolism
-
Proto-Oncogene Proteins / genetics
-
Proto-Oncogene Proteins / metabolism
-
Repressor Proteins / metabolism
-
Signal Transduction
Substances
-
Antigens, Neoplasm
-
Cell Adhesion Molecules
-
Cell Cycle Proteins
-
Epithelial Cell Adhesion Molecule
-
Polycomb-Group Proteins
-
Proto-Oncogene Proteins
-
Repressor Proteins
-
Protein Serine-Threonine Kinases